Form 4: Instil Bio Director Neil Gibson Granted 6,500 Stock Options

Instil Bio, Inc. Director Neil W. Gibson was granted 6,500 stock options with an exercise price of $26.75, vesting over 12 months, as disclosed in a recent SEC Form 4 filing.

Summary

• Neil W. Gibson, a Director of Instil Bio, Inc. (TIL), was granted 6,500 stock options.
• The options have an exercise price of $26.75 per share.
• The transaction date for this grant was May 28, 2025.
• The options will vest in 12 substantially equal monthly installments, commencing on June 28, 2025, contingent on Mr. Gibson's continuous service.
• Any unvested portion of the option will fully vest on the date of the next annual stockholder meeting, subject to continuous service.
• Full vesting will also occur upon Mr. Gibson's death, Disability, or a Change in Control, as defined in the company's 2021 Equity Incentive Plan.
• The expiration date for these stock options is May 27, 2035.
• Following this transaction, Mr. Gibson beneficially owns 6,500 derivative securities directly.

Sentiment

Score: 6

Explanation: Slightly positive. The grant of stock options to a director is a standard practice that aligns management's interests with shareholders, which is generally viewed favorably. There are no negative implications from this specific filing.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continuous service and commitment from the director.

Future Outlook

The stock options granted to Director Neil W. Gibson are subject to a future vesting schedule, with monthly installments commencing on June 28, 2025, and potential full vesting at the next annual stockholder meeting or upon specific events like death, disability, or a change in control, aligning his future compensation with company performance.

Industry Context

Stock option grants are a common form of equity compensation for directors and executives in the biotechnology and pharmaceutical industries, aiming to align leadership's financial interests with long-term shareholder value creation. This grant to an Instil Bio director is consistent with typical compensation practices in the sector.

Comparison to Industry Standards

• The grant of stock options to a director is a standard practice in the biotechnology industry for executive and board compensation, aiming to align interests with long-term company performance.
• The vesting schedule, including monthly installments and accelerated vesting upon specific events (e.g., change in control), is typical for equity incentive plans across publicly traded companies, including those comparable to Instil Bio in the biotech space.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders if the stock price increases.

Next Steps

• The stock options will begin vesting in 12 substantially equal monthly installments starting June 28, 2025.
• The options will continue to vest subject to the reporting person's continuous service.

Key Dates

Keywords

Instil Bio, TIL, Stock Option, Director Compensation, Equity Incentive Plan, Insider Transaction, Form 4, Vesting Schedule